FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海實業城市開發集團有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00563 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.04 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.04 HKD | | 400,000,000 ...

因此，于本公告日期，金钟间接持有公司控股权益(即公司已发行股份约63.16%)、上海实业城市开发集 团有限公司(00563)控股权益(即上实城开已发行股份约70.44%)及上海实业环境控股有限公司(00807)控 股权益(即上实环境已发行股份约50.12%)。上实城开及上实环境均为公司的非全资附属公司。由于上实 集团、上海上实及金钟目前及在所有重要时刻均由上海市政府实益全资拥有，故公司、上实城开及上实 环境的最终控制权仍由上海市政府拥有。因此，于内部重组建议完成后，公司、上实城开及上实环境的 最终控制权并无出现变动。 上海实业控股(00363)发布公告，董事会已获公司直接控股股东上实集团告知，内部重组建议于2025年 12月29日完成，而金钟已注册为上实集团全部已发行股份的拥有人。为免生疑问，上实集团的注册拥有 权于内部重组建议完成后变更至金钟并不涉及收购投票权。投票权目前由上海市政府拥有，并于所有重 要时刻一直由上海市政府拥有。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.04 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.04 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 ...

Core Viewpoint - The company has entered into a conditional equity transfer agreement to sell a 49% stake in Shanghai Shanshi Medical Beauty Hospital Co., Ltd. for a total consideration of RMB 73.598 million, which aligns with its strategy to optimize asset allocation and focus on core business development [1] Group 1: Transaction Details - The agreement involves Shanghai Huashi and Shanghai Lingfeng Medical, with Shanghai Lingfeng Medical agreeing to purchase the stake from Shanghai Huashi and the company's wholly-owned subsidiary, Shanghai Dajiankang Management [1] - Upon completion of the transaction, the company will no longer hold any equity in the target company, which will be fully owned by Shanghai Lingfeng Medical [1] Group 2: Strategic Implications - The sale allows the company to recover and reallocate capital, streamline its investment portfolio, and concentrate resources on its main business, thereby enhancing operational efficiency and capital discipline [1] - This transaction is part of the company's ongoing strategy to improve cash flow and support long-term sustainable growth [1]

Group 1 - The target company is owned by Shanghai Lingfeng Medical (51%), Shanghai Huashi (30%), and Shanghai Dasheng Management (19%), with the group holding a 19% indirect interest classified as an investment in an associate [1] - Following the completion of the transaction, the company will no longer hold any interest in the target company, which will be wholly owned by Shanghai Lingfeng Medical, and the target company will cease to be an associate of the company [1] - The group aims to recover and reallocate capital through the sale, streamline its investment portfolio, and focus resources on core business operations to enhance operational efficiency and capital discipline [1] Group 2 - Shanghai Dasheng Management, a wholly-owned subsidiary of the company, has entered into a conditional equity transfer agreement with Shanghai Huashi and Shanghai Lingfeng Medical to sell a combined 49% stake in the target company, Shanghai Shanshi Medical Beauty Hospital Co., Ltd., for a total consideration of RMB 73.598 million [2]

Core Viewpoint - The company is divesting its 19% stake in Shanghai Shanshi Medical Beauty Hospital to streamline its investment portfolio and focus on core business operations, enhancing operational efficiency and capital discipline [1] Group 1: Transaction Details - The company’s wholly-owned subsidiary, Shanghai Shanshi Urban Development, entered into a conditional equity transfer agreement on November 13, 2025, with Shanghai Huashi and Shanghai Lingfeng Medical [1] - The total consideration for the 49% stake in the target company is RMB 73.598 million [1] - Post-transaction, the target company will be wholly owned by Shanghai Lingfeng Medical, and the company will no longer hold any equity in it [1] Group 2: Strategic Implications - The divestment allows the company to recover and reallocate capital, streamline its investment portfolio, and concentrate resources on its main business [1] - This move aligns with the company's strategy to optimize asset allocation, improve cash flow, and focus on core business development [1] - The transaction is expected to support the company in achieving long-term sustainable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：563） 關連交易 出售於聯營公司之股權 出售事項 董事會宣佈，上實城開上海大健康管理於二零二五年十一月十三日與上海華氏及 上海凌風醫療訂立股權轉讓協議，據此，上海華氏及上實城開上海大健康管理有 條件同意出售而上海凌風醫療有條件同意購買有關股權，合共佔目標公司之 49%，總代價為人民幣73,598,000元。 於本公告日期，目標公司由上海凌風醫療、上海華氏及上實城開上海大健康管理 分別擁有51%、30%及19%。本集團於目標公司之19%間接權益，在本公司綜合 財務報表中分類為於聯營公司之投資。完成後，本公司將不再擁有目標公司之任 何權益，目標公司將由上海凌風醫療全資擁有。目標公司將不再為本公司之聯營 公司。 上市規則之涵義 於本公告日期，(i)上海凌風醫療為本公司控股股東上實集團之全資附屬公司； 及(ii)上海華氏為上海醫藥（集團）之全資附屬公司，上海醫藥（集 ...

Group 1 - The company, Shanghai Urban Development (00563.HK), announced the appointment of executive director Zhou Yadong and independent non-executive director Chen Haohua as members of the nomination committee, effective from November 12, 2025 [1]

Group 1 - The company, Shanghai Urban Development (00563), announced the appointment of Ms. Zhou Yadong as an executive director and Dr. Chen Haohua as an independent non-executive director to the company's nomination committee, effective from November 12, 2025 [1]

上海實業城市開發集團有限公司（「本公司」）董事（「董事」）會（「董事會」）現共有七名 董事，每名董事的姓名、角色和職能載列如下： 執行董事 黃海平先生 （主席） 李忠輝先生 （總裁） 周亞棟女士 獨立非執行董事 杜惠愷先生， B.B.S.，太平紳士 范仁達博士 李家暉先生， M.H 陳浩華博士 （於百慕達註冊成立之有限公司） （股份代號：563） 董事名單與其角色和職能 本公司已設立四個董事委員會，並制定有關職權範圍。下表提供各董事會成員於各 董事委員會所擔任的職務。 | | 董事委員會 | 審核 | 提名 | 薪酬 | 投資評證 | | --- | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | 委員會 | | 黃海平先生 | | | C | | | | 李忠輝先生 | | | | | M | | 周亞棟女士 | | | M | | M | | 杜惠愷先生， | B.B.S.，太平紳士 | M | M | C | | | 范仁達博士 | | M | M | M | C | | 李家暉先生， | M.H | C | | | | | 陳浩華博士 ...